Search

Your search keyword '"Borghetti, Alberto"' showing total 10 results
Start Over Author "Borghetti, Alberto" Journal aids research and human retroviruses
10 results on '"Borghetti, Alberto"'

2. Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life

Author

Iannone, Valentina, primary, Farinacci, Damiano, additional, D'Angelillo, Anna, additional, Dusina, Alex, additional, Lamanna, Francesco, additional, Passerotto, Rosanna, additional, Baldin, Gianmaria, additional, Visconti, Elena, additional, Tamburrini, Enrica, additional, Borghetti, Alberto, additional, Di Giambenedetto, Simona, additional, and Ciccullo, Arturo, additional

Published
2022
Full Text
View/download PDF

3. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice

Author

Baldin, Gianmaria, primary, Ciccullo, Arturo, additional, Lombardi, Francesca, additional, D'Angelillo, Anna, additional, Dusina, Alex, additional, Emiliozzi, Arianna, additional, Farinacci, Damiano, additional, Moschese, Davide, additional, Picarelli, Chiara, additional, Borghetti, Alberto, additional, and Di Giambenedetto, Simona, additional

Published
2021
Full Text
View/download PDF

5. Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital

Author

Borghetti, Alberto, primary, Bellino, Stefania, additional, Lombardi, Francesca, additional, Whalen, Matteo, additional, Belmonti, Simone, additional, Moschese, Davide, additional, Ciccullo, Arturo, additional, Tamburrini, Enrica, additional, Baldin, Gianmaria, additional, Dusina, Alex, additional, Visconti, Elena, additional, Emiliozzi, Arianna, additional, Lamonica, Silvia, additional, Pezzotti, Patrizio, additional, and Di Giambenedetto, Simona, additional

Published
2021
Full Text
View/download PDF

6. People Living with HIV in the COVID-19 Era: A Case Report

Author

Farinacci, Damiano, primary, Ciccullo, Arturo, additional, Borghetti, Alberto, additional, Visconti, Elena, additional, Tamburrini, Enrica, additional, Izzi, Immacolata Maria, additional, Cauda, Roberto, additional, Di Giambenedetto, Simona, additional, and Pallavicini, Federico, additional

Published
2021
Full Text
View/download PDF

9. Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores.

Author

Ciccullo A, Iannone V, Farinacci D, Steiner RJ, Lombardi F, Carbone A, Salvo PF, Baldin G, Borghetti A, and Di Giambenedetto S

Abstract

The Aim of this study is to assess the cardiovascular safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF). We analyzed data from 37 virologically suppressed people living with HIV starting DOR/3TC/TDF, collecting viro-immunological and metabolic parameters as well as the 10-year risk of cardiovascular disease (10Y-CD) using both the Framingham risk score and D:A:D score.After 48 weeks, we observed a significant reduction in 10Y-CD both via the Framingham score (-0.7, p = .021) and the D:A:D score (-0.41, p = .012). After 96 weeks, we registered a significant reduction in 10Y-CD calculated via the D:A:D score (-0.98, p = .009). Regarding serum lipid markers, after 48 weeks we observed a significant reduction in total cholesterol (-17 mg/dL, p < .001), triglycerides (-21 mg/dL, p = .015), and LDL cholesterol (-8 mg/dL, p = .022). After 96 weeks, we registered a significant reduction in total cholesterol (-19 mg/dL, p < .001). DOR/3TC/TDF has shown a favorable metabolic profile, with a significant reduction in 10Y-CD, independently from the use of lipid-lowering drugs.

Published
2024
Full Text
View/download PDF

10. Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy.

Author

Farinacci D, Iannone V, D'Angelillo A, Borghetti A, Passerotto RA, Lamanna F, and Di Giambenedetto S

Subjects
Humans, Darunavir, Cobicistat therapeutic use, Ritonavir therapeutic use, Ritonavir adverse effects, Drug Therapy, Combination, Viral Load, HIV Infections drug therapy, Anti-HIV Agents adverse effects, Dyslipidemias drug therapy, Dyslipidemias chemically induced
Abstract

Regimens containing darunavir are one of the first one with two drugs that demonstrated good efficacy as a simplification strategy. We wanted to describe the characteristics of patients followed in our center on a dual therapy regimen containing darunavir evaluating the metabolic aspects during follow-ups. We collected data from 208 patients switching to lamivudine plus darunavir with either ritonavir or cobicistat between 2010 and 2019. In all patients we found an increase in low-density lipoprotein (LDL), with no rising in creatinine, total cholesterol, or triglycerides. Twenty-five patients reached 120 weeks of follow-up. In these patients, no significant metabolic changes were described without concomitant treatment with drugs for dyslipidemia. These regimens seem to be more tolerable in metabolic profile compared with the data concerning three-drug therapies, leading only to a slight increase in LDL. The main reason for discontinuation was for a single-tablet therapy. None of the patients started treatment for dyslipidemia.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results